Cells (Mar 2022)

Altered Plasma Fatty Acid Abundance Is Associated with Cachexia in Treatment-Naïve Pancreatic Cancer

  • Kristyn Gumpper-Fedus,
  • Phil A. Hart,
  • Martha A. Belury,
  • Olivia Crowe,
  • Rachel M. Cole,
  • Valentina Pita Grisanti,
  • Niharika Badi,
  • Sophia Liva,
  • Alice Hinton,
  • Christopher Coss,
  • Mitchell L. Ramsey,
  • Anne Noonan,
  • Darwin L. Conwell,
  • Zobeida Cruz-Monserrate

DOI
https://doi.org/10.3390/cells11050910
Journal volume & issue
Vol. 11, no. 5
p. 910

Abstract

Read online

Cachexia occurs in up to 80% of pancreatic ductal adenocarcinoma (PDAC) patients and is characterized by unintentional weight loss and tissue wasting. To understand the metabolic changes that occur in PDAC-associated cachexia, we compared the abundance of plasma fatty acids (FAs), measured by gas chromatography, of subjects with treatment-naïve metastatic PDAC with or without cachexia, defined as a loss of > 2% weight and evidence of sarcopenia (n = 43). The abundance of saturated, monounsaturated, and polyunsaturated FAs was not different between subjects with cachexia and those without. Oleic acid was significantly higher in subjects with cachexia (p = 0.0007) and diabetes (p = 0.015). Lauric (r = 0.592, p = 0.0096) and eicosapentaenoic (r = 0.564, p = 0.015) acids were positively correlated with age in cachexia patients. Subjects with diabetes (p = 0.021) or both diabetes and cachexia (p = 0.092) had low palmitic:oleic acid ratios. Linoleic acid was lower in subjects with diabetes (p = 0.018) and correlated with hemoglobin (r = 0.519, p = 0.033) and albumin (r = 0.577, p = 0.015) in subjects with cachexia. Oleic or linoleic acid may be useful treatment targets or biomarkers of cachexia in patients with metastatic PDAC, particularly those with diabetes.

Keywords